Biosimilar medicines used for cancer therapy in Europe: a review

• Type: Another Publication in an International Scientific Journal
• Date: 2019

Authors

Santos, SB (Author) Other; Sousa Lobo JM (Author) FFUP; Silva, AC (Author) Other

Journal

Title: Drug Discovery Today

Vol. 24

Pages: 293-299

ISSN: 1359-6446

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 1 Citation

Scopus - 0 Citations

Other information

Authenticus ID: P-00P-PXR

DOI: 10.1016/j.drudis.2018.09.011

Abstract (EN): This article provides an updated review of the biosimilar medicines approved for cancer therapy in the European Union (EU). First we discuss the most relevant aspects for the development and approval of biosimilar medicines. We then present the oncological biosimilar drugs currently used, which include epoetins (alpha and zeta), filgrastim, and monoclonal antibodies (rituximab, trastuzumab and bevacizumab). Among the clinical applications of biosimilar medicines, cancer therapy remains the main target area and more approved biosimilars are expected over the next few years, providing cost-effective drugs to more patients. Furthermore, comprehensive pharmacovigilance studies are going on, monitoring the marketed biosimilars, and providing more feasible information to clinicians regarding the safety and efficacy of these medications.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 7